Cargando…
Brexpiprazole has a low risk of dopamine D(2) receptor sensitization and inhibits rebound phenomena related to D(2) and serotonin 5‐HT(2A) receptors in rats
BACKGROUND: Long‐term antipsychotic treatment in patients with schizophrenia can induce supersensitivity psychosis and tardive dyskinesia which is thought to be caused by dopamine D(2) receptor sensitization. We evaluated the effects of brexpiprazole on D(2) receptor sensitivity after subchronic tre...
Autores principales: | Amada, Naoki, Akazawa, Hitomi, Ohgi, Yuta, Maeda, Kenji, Sugino, Haruhiko, Kurahashi, Nobuyuki, Kikuchi, Tetsuro, Futamura, Takashi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7292306/ https://www.ncbi.nlm.nih.gov/pubmed/31487433 http://dx.doi.org/10.1002/npr2.12076 |
Ejemplares similares
-
Discovery research and development history of the dopamine D(2) receptor partial agonists, aripiprazole and brexpiprazole
por: Kikuchi, Tetsuro, et al.
Publicado: (2021) -
Synergistic anti‐depressive effect of combination treatment of Brexpiprazole and selective serotonin reuptake inhibitors on forced swimming test in mice
por: Amada, Naoki, et al.
Publicado: (2023) -
Brexpiprazole Reduces 5-HT7 Receptor Function on Astroglial Transmission Systems
por: Fukuyama, Kouji, et al.
Publicado: (2022) -
Anatomical relationships between serotonin 5-HT(2A) and dopamine D(2) receptors in living human brain
por: Ishii, Tatsuya, et al.
Publicado: (2017) -
Biophysical validation of serotonin 5-HT(2A) and 5-HT(2C) receptor interaction
por: Felsing, Daniel E., et al.
Publicado: (2018)